- Open Access
Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice
Critical Care volume 15, Article number: R153 (2011)
Acute kidney injury following surgery incurs significant mortality with no proven preventative therapy. We investigated whether the α2 adrenoceptor agonist dexmedetomidine (Dex) provides protection against ischemia-reperfusion induced kidney injury in vitro and in vivo.
In vitro, a stabilised cell line of human kidney proximal tubular cells (HK2) was exposed to culture medium deprived of oxygen and glucose. Dex decreased HK2 cell death in a dose-dependent manner, an effect attenuated by the α2 adrenoceptor antagonist atipamezole, and likely transduced by phosphatidylinositol 3-kinase (PI3K-Akt) signaling. In vivo C57BL/6J mice received Dex (25 μg/kg, intraperitoneal (i.p.)) 30 minutes before or after either bilateral renal pedicle clamping for 25 minutes or right renal pedicle clamping for 40 minutes and left nephrectomy.
Pre- or post-treatment with Dex provided cytoprotection, improved tubular architecture and function following renal ischemia. Consistent with this cytoprotection, dexmedetomidine reduced plasma high-mobility group protein B1 (HMGB-1) elevation when given prior to or after kidney ischemia-reperfusion; pretreatment also decreased toll-like receptor 4 (TLR4) expression in tubular cells. Dex treatment provided long-term functional renoprotection, and even increased survival following nephrectomy.
Our data suggest that Dex likely activates cell survival signal pAKT via α2 adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide reno-protection.
Perioperative acute kidney injury (AKI) is an abrupt deterioration of renal function that occurs as a complication of major cardiothoracic, vascular and transplant surgery [1–5]. In this setting AKI is associated with prolonged hospitalization and mortality rates as high as 60% [6, 7]; including a 25-fold increase in mortality following cardiac valve surgery [7, 8]. Furthermore, patients who sustain AKI and make a full recovery retain a higher risk of long-term mortality .
Among its diverse etiologic factors, ischemia-reperfusion injury (IRI) remains the foremost cause of perioperative AKI . Following a transient deprivation of total or regional vascular supply to the kidney, restoration of blood flow inflicts continuous and severe damage in the post-ischemic renal parenchyma, characterized histopathologically as vascular, tubular, and inflammatory perturbations . A growing body of evidence demonstrates that the TLR family, particularly TLR-4, plays the dominant role in mediating the deleterious effects in renal IRI [12, 13]. In addition, damage-associated molecules such as HMGB-1 have been postulated as a TLR-4 ligand that drives the robust inflammatory response in post-ischemic kidney [14, 15].
The current clinical management of perioperative AKI is supportive ; therefore, novel prophylactic (pre-insult therapy) and therapeutic (post-insult therapy) is required to reduce the burden of AKI in the perioperative period. The α2 adrenoceptor agonist dexmedetomidine exerts sedative, analgesic, hemodynamic stabilizing, anti-inflammatory and diuretic effects . It is a highly potent α2 adrenergic agonist with a remarkable binding specificity for the α2 adrenoceptor. Novel organoprotective properties of dexmedetomidine have been explored in the brain, heart and renal injury [18–21]. Indeed α2 adrenoceptors are distributed widely in the renal proximal, distal tubules and peri-tubular vasculature. Clinically α2 adrenoceptor agonists enhance urine flow rate and perioperative renal function [22, 23]; however, the underlying molecular mechanisms remain unknown. Animal studies have suggested that α2 adrenoceptor agonists are renoprotective as a class; their mechanism largely revolving around modulating vasoreactivity [21, 24, 25]. Herein we report that dexmedetomidine protects against IRI to the kidney in mice and that the mechanism is due to a decrease in the level of renal cell death and suppression in the HMGB-1-TLR-4 inflammatory circuit.
Materials and methods
A stabilised cell line of kidney cells (HK2), derived from adult human kidney proximal tubular cells, was used in our experiments (European Cell Culture Collection, Salisbury, UK). Cells were cultured in RPMI 1640 medium, 1% L-glutamine 100 nM, 1% penicillin-streptomycin 100 U/ml, 5% fetal calf serum (Gibco, Invitrogen Ltd, Paisley, UK) in a humidified atmosphere containing 5% CO2. They were used soon after reaching 80% confluence.
Cell injury was provoked by oxygen glucose deprivation (OGD) as we reported previously . Briefly, OGD solution (116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 1.0 mM NaH2PO4, 26 mM NaHCO3 and 1.8 mM CaCl2; pH 7.4) was bubbled through with pure nitrogen gas for 15 minutes using sterile Drechsel bottles to remove oxygen from the solution. Cells were washed sequentially with warmed HEPES buffer solution (120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 15 mM anhydrous D-glucose and 20 mM HEPES) and warmed prepared OGD solution. The multi-well plates were then cultured with 1 ml of warmed OGD solution and incubated in air tight gas chambers for the indicated period exposed to 95% nitrogen, 5% CO2 at 37°C with or without dexmedetomidine (0.001 to 0.1 nM) (Orion Pharm (UK) Ltd, NewburyBerkshire, UK)+/- atipamezole (1 nM). After OGD treatment, cells were removed from the gas chamber, the OGD solution was replaced with warmed culture medium and placed in a humidified 5% CO2 incubator at 37°C for 24 hrs. Cell viability was assessed using an 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Merck KGaA, Darmstadt, Germany) assay .
Other cell cohorts were treated with dexmedetomidine (0.1 nM) in the absence of OGD with or without the highly selective inhibitors of PI3-Akt, LY294002 (50 μM), and mitogen-activated protein kinase (MAPK), PD98059 (50 μM), respectively.
Ten-week-old male C57BL/6J mice weighing 20 to 25 g were housed in temperature and humidity-controlled cages with free access to sterile acidified water and irradiated food in a specific pathogen-free facility at Imperial College London. This study was approved by the ethics committee of Imperial College London and the UK Home Office (PPL: 70/6966) and all procedures were performed strictly under the United Kingdom Animals (Scientific Procedures) Act 1986.
Renal ischemia-reperfusion injury
Dexmedetomidine (25 μg/kg, i.p., based on the previous organ protection studies [19, 27]) was administered 30 minutes before or immediately after renal ischemia-reperfusion injury (rIRI). One cohort was treated with the α2 adrenoceptor antagonist atipamezole (250 μg/kg, i.p. [19, 27]) prior to the administration of dexmedetomidine. The naive group and the rIRI group served as negative and positive controls, respectively. The animals were sacrificed 24 hr after rIRI. Kidneys were harvested for H&E and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. All assessments were made by an investigator who was blinded to the experimental protocols. rIRI was induced either by bilateral renal pedicle clamping for 25 minutes to produce moderate renal injury, or by right renal pedicle clamping for 40 minutes and left nephrectomy to produce life-threatening renal injury, under 1.5% isoflurane surgical anesthesia. Sham-operated mice had dissection as above, but with no occlusion of the renal vessel. The intra-abdominal temperature was maintained at 36 ± 0.1°C with a heating pad which was servo-adjusted by a temperature controller (Engineering Inc, Stamford, CT, USA) throughout the experiment. For survival experiments, mice were monitored on a daily basis with a scoring assay based on body weight, activity and general appearance as reported previously. Any animals that scored > 7 were euthanized. All animals received 0.5 ml saline i.p. injection per every 6 hrs for the first 24 hrs after experiments.
Proteins were extracted from treated HK2 cells lines or frozen kidney samples by cell disruption in cell lysis buffer (New England Biolabs, Hitchin, Hertfordshire, UK) and sonication with an ultrasonic probe, followed by centrifugation at 10,000 g for 10 minutes at 4°C. The supernatant was collected for Western blotting. Samples containing 30 μg of extracted protein, as determined by the Bradford protein assay (BioRad, Hemel Hempstead Hertfordshire, UK), were loaded on a NuPAGE 4 to 12% Bis-Tris gel (Invitrogen, Paisley, UK) for protein fractionation by electrophoresis and then electro-transferred to a nitrocellulose membrane (Hybond ECL; Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Blots were blocked with 5% non-fat dry milk in TBS (pH8.0, containing 0.1% Tween-20), and probed with appropriate antibodies (1:1,000 Akt, p-Akt and TLR4- all from followed Cell Signaling, Hitchin, Hertfordshire, UK; 1:100 TLR4- Santa Cruz, Wembley Middlesex, UK) by HRP-conjugated secondary antibodies (Cell Signaling) and visualisation with enhanced chemiluminescence (Cell Signaling). α-tubulin (1:2,000, Sigma, Dorset, UK) was used as internal control. Densitometry analysis were preformed and normalized with α-tubulin and then presented as percentage of control.
The sum score was calculated from the analysis of 10 cortical tubules/cross-section stained with H&E (10 sections/kidney) by using a modified scoring system ; 0, no damage. 1, mild damage: rounded epithelial cells and dilated tubular lumen; 2, moderate damage: flattened epithelial cells, loss of nuclear staining and substantially dilated lumen; 3, severe damage: destroyed tubules with no nuclear staining of epithelial cells.
The second l death of tubular epithelial cells was detected by in situ TUNEL assay Obiogene, Cambridge, UK) according to the manufacturer's instructions. The fixed cryostat sections were washed with PBS and then treated with proteinase K (20 μg/ml) at room temperature for 15 minutes. For positive controls, sections were treated with nuclease (R&D System, Abingdon, UK) at 37°C for 15 minutes. The sections were quenched in 3% hydrogen peroxide in PBS for five minutes. The quenched sections were labelled with TDT enzyme at 37°C for 1 hour in a humidified chamber and subsequently incubated with anti-digoxygenin conjugated to horseradish peroxidase for 30 minutes at room temperature. They were then stained with DiAminoBenzidine (DAB). The sum of the TUNEL+ cells in an objective grid from 10 areas of randomly selected renal cortex was counted under a 40 × objective lens by an investigator who was blinded to the experimental protocol.
The other fixed cryostat sections were incubated with 3% hydrogen peroxide for 30 minutes to quench endogenous peroxidase activity. Sections were blocked for 30 minutes in wash buffer phosphate buffered saline tween-20 containing 3% goat serum and then incubated at 4°C overnight with goat anti-mouse TLR-4 (Santa Cruz Biotechnology, Wembley, Middlesex, UK) diluted 1:250 in PBS and 1% goat serum. After washing with PBST, sections were incubated with biotinylated donkey anti-goat IgG (Santa Cruz) diluted 1:250 in PBS and then labelled with VectaStain Elite ABC solution (Vector Labs, Orton Southgate, Peterborough, UK). After further washes in PBS, staining was developed with DiAminoBenzidine (DAB) with nickel. Slides were washed in PBS buffer, dH20 and then in 100% ethanol for 10 minutes and xylene for 10 minutes before covered with cover glass for micrograph taken.
Plasma creatinine, urea and HMGB1
Both creatinine and urea were measured in 100 μl of plasma with an Olympus AU640 analyzer (Diamond Diagnostics, Watford, UK). Plasma HMGB1 was measured by ELISA according to the manufacturer's instruction (IBL International GmbH, Hamburg, Germany)
Statistical comparison was by ANOVA followed by post hoc Student-Newman Keul's test where appropriate. Survival was analyzed by Kaplan-Meier test. A P < 0.05 was considered as statistically significant.
Dexmedetomidine confers in vitroprotection via Akt activation
To determine whether dexmedetomidine provides reno-protection in vitro, we exposed HK2 cells, a well-characterized human kidney proximal tubular cell line to oxygen and glucose deprivation (OGD), established to mimic the ischemic phase of renal ischemic reperfusion injury in our previous studies . Cell viability analysis using MTT assay showed a time-dependent induction of injury with marked cell death (60% reduction in viability) occurring after 180-minutes OGD (0.39 ± 0.07 versus 1.0 ± 0.04 of control; P < 0.05) and was, therefore, used in subsequent experiments to determine the cytoprotective effects of dexmedetomidine (Figure 1A).
Incubating HK2 cells with dexmedetomidine (0.001 to 0.1 nM) before OGD exposure dose-dependently inhibited injury (Figure 1B). Treatment with 0.1 nM dexmedetomidine increased cell viability to 94% (from 0.35 ± 0.10 to 0.94 ± 0.12; P < 0.05), compared with the positive control (OGD). The cytoprotective effect of dexmedetomidine was abolished by co-treatment with the α2 adrenoceptor antagonist, atipamezole (1 nM), suggesting dexmedetomidine confers protection to renal epithelial cells via α2 adrenoceptor activation. Treatment of naïve controls with either dexmedetomidine (0.1 nM) or atipamezole (1 nM) did not significantly decrease cell viability (0.8 ± 0.13 and 1.0 ± 0.25 respectively versus control). Therefore, neither dexmedetomidine nor atipamezole were cytotoxic to HK2 cells.
Activation of the Akt pathway plays a key role in cytoprotective signaling and has been demonstrated to ameliorate renal injury in IRI mice . To determine whether dexmedetomidine activates Akt, we measured phosphorylated Akt (pAkt) levels in HK2 cells incubated with media containing 0.1 nM dexmedetomidine for 5, 10, 20, 30 and 45 minutes (Figure 2A). Dexmedetomidine induced significant increases in pAkt at all time-points; whereas, total Akt protein levels were not altered. The magnitude of Akt phosphorylation peaked after 20 minutes (2.91 ± 0.54 versus 1.0 ± 0.25 of control; P < 0.01) and was used in subsequent experiments to identify upstream mediators of Akt activation. Atipamezole reduced, but could not completely abolish dexmedetomidine-induced phosphorylation of Akt, suggesting that pAkt activation may be partially dependent on α2 adrenoceptors (Figure 2B). LY294002 and PD98059 have been shown to act in vivo as highly selective inhibitors of PI3-Akt and mitogen-activated protein kinase (MAPK) cascades respectively. LY294002 (50 μM) rather than PD98059 (50 μM) completely abolished dexmedetomidine-induced activation of Akt (0.6 ± 0.2 versus 1.7 ± 0.2 of Dex only; P < 0.01), indicating that pAkt was generated in a PI3K-dependent manner.
Dexmedetomidine reduces IRI pathological changes in vivo
Next, we investigated whether dexmedetomidine provides protection against renal IRI in mice when the renal pedicle of both kidneys are clamped for 25 minutes. Twenty-four hours after IRI, kidneys and blood were harvested for histological assessment and for renal function (serum creatinine and urea), respectively. Histopathological assessment of cortical tubular damage was conducted by an investigator blinded to the experimental protocol. IRI significantly increased histopathological scoring (151 ± 45 versus 19 ± 9 of naive control; P < 0.01), as illustrated by severe tubular lumen dilatation, flattened renal epithelial cells and loss of nuclear staining (Figure 3C). Pre- and post-treatment with dexmedetomidine (25 μg/kg) resulted in a 53% and 38% reduction in damage (72 ± 15; P < 0.01 and 94 ± 19; P < 0.05) compared with IRI group, respectively (Figure 3G). Atipamazole (250 μg/kg) given prior to dexmedetomidine pre-treatment significantly inhibited the reno-protective action (142 ± 38; P < 0.01). Treatment of naïve animals with dexmedetomidine had no deleterious effects on kidney tissue (11 ± 9 versus 19 ± 9 of naïve control), in agreement with in vitro findings.
To evaluate kidney damage at the cellular level, we used terminal deoxynucleotidyl transferase-mediated digoxigenindeoxyuridine nick-end labeling (TUNEL) staining to detect dead tubular cells. IRI significantly increased TUNEL-positive cells (85.0 ± 28.5 versus 6.2 ± 5.3 of naive control, P < 0.01). Pre- and post-treatment with dexmedetomidine resulted in a 72% and 58% reduction in cell death (23.8 ± 7.5 and 35.2 ± 18.2; both P < 0.01), compared to IRI mice, respectively (Figure 4). Cellular renoprotection was abolished when dexmedetomidine pre-treatment was preceded by atipamazole (89.0 ± 14.3; P < 0.01). No difference in TUNEL staining was seen when dexmedetomidine was given to mice not subjected to renal injury (8.0 ± 2.3; NS versus naïve controls).
A similar pattern of changes were noted in renal function. After IRI, the plasma creatinine rose from 34.6 ± 2.2 to 81.8 ± 6.4 μM/L. Pre-treatment with dexmedetomidine was protective, with creatinine showing no significant difference from animals not subjected to renal injury. When dexmedetomidine pre-treatment was preceded by atipamazole, this abrogated the protective effect so that creatinine was significantly higher (85.8 ± 37.8; P < 0.01) than that seen in the uninjured animals (Figure 5A). Similarly, IRI-induced increase in plasma urea (from 5.4 ± 0.2 to 27.9 ± 5.0 mM/L) was significantly reduced following pre-treatment with dexmedetomidine (18.22 ± 4.3; P < 0.05), an effect that was completed abolished by atipamazole (30.0 ± 4.7; P < 0.01) (Figure 5B).
Dexmedetomidine attenuates Toll-like Receptor 4 (TLR4) expression in tubular cells
To investigate the molecular mechanisms of dexmedetomidine-induced renoprotection, we assessed toll-like receptor 4 (TLR4) expression in situ and its upstream mediator, high mobility group box-1 (HMGB1) nuclear protein in plasma. HMGB1 and TLR4 signaling play a pivotal role in the coordination of inflammatory responses in renal IRI [30, 31]. There was no detectable staining when primary antibody was omitted (data not shown) while TLR4 expression was at very minimal level in the naïve control (Figure 6A). However, marked increases in renal TLR4 expression were detected in IRI mice using in situ immunostaining (Figure 6B) and Western blot (Figure 6E). Pre-treatment with dexmedetomidine resulted in a dramatic decrease in TLR4 expression (Figure 6C) to a level even lower than that of control (Figure 6E), which was effectively restored to even the higher level than that in the control by atipamazole (Figure 6D). Similarly, plasma HMGB1 levels were dramatically elevated in IRI mice (from 25.9 ± 2.9 to 122.4 ± 40.3 pg/ml; P < 0.001), compared to control. Pre- and post-treatment with dexmedetomidine significantly attenuated the rise in HMGB1 (58.1 ± 19.5 and 61.5 ± 28.3; both P < .01) compared to IRI mice, respectively (Figure 6F). The protective effects of dexmedetomidine pre-treatment on HMGB1 upregulation were partially inhibited by atipamazole (61.5 ± 28.3; P < 0.05) relative to IRI mice. Together, these findings suggest that HMGB1 and TLR4 pro-inflammatory signaling in renal IRI may be partially dependent on an α2 adrenoceptor-mediated mechanism. No change was seen in naïve mice treated with dexmedetomidine.
Dexmedetomidine protects from renal failure
To assess whether dexmedetomidine was also effective in the context of a more severe insult to renal function, we performed additional experiments in which the right renal pedicle was clamped for 40 minutes and the left kidney was removed. The mean value of plasma creatinine and urea rose more than seven-fold at 24 h after IRI (to 233.5 ± 34.1 μM/L and 62.1 ± 10.2 mM/L, respectively). Administration of dexmedetomidine either before or after IRI significantly attenuated the rise in creatinine and urea values (both P < 0.01) relative to IRI controls (Figure 7A, B). Atipamezole treatment did not change creatinine and urea in IRI mice but significantly inhibited the renal protective effects of dexmedetomidine (P < 0.001, all comparisons). Long-term survival (no signs of illness at seven days) was noted in 70% and 60% of animals treated with dexmedetomidine before and after renal IRI. By contrast, animals not treated with dexmedetomidine or receiving atipamezole combined dexmedetomidine fared much worse. Within three days, 65% of these animals were dead (either spontaneously or killed because of severe ill health measured against previously reported predefined criteria  and no animals survived beyond five days after IRI (P < 0.001 versus pre- and post-dexmedetomidine groups; Figure 7C).
Our work showed that dexmedetomidine induced a sustained up-regulation of phospho-Akt and protected against oxygen-glucose deprivation in a human kidney cell line; its effects were blocked by atipamezole. In vivo, dexmedetomidine attenuated the HMGB-1/TLR-4 pathway, preserving tubular architecture and reducing cell death. Associated with the improved histological findings, the level of renal dysfunction was minimized and renal failure was prevented after severe IRI resulting in improved survival. The organ-protective effect was abolished with α2 adrenoreceptor antagonist, indicating that dexmedetomidine acted in an α2 adrenoreceptor dependent manner.
Our data demonstrated a significantly increased expression of phospho-Akt in cultured tubular cells after treatment with dexmedetomidine (Figure 2). This was blocked partially by an α2 adrenoceptor antagonist and significantly reduced by a PI3K inhibitor, indicating that the dexmedetomidine activates Akt via both α2 adrenoceptor dependent and independent-PI3K coupling. In summation, we consider it likely that the activation of PI3K-Akt is one of the survival cascades activated by dexmedetomidine to induce cytoprotection (Figure 1). The PI3K-Akt pathway promotes cell survival by phosphorylating the proapoptotic Bcl-2-associated death promotor (BAD) and up-regulating the expression of anti-apoptotic Bcl-2 and Bcl-xl , inhibiting the caspase-controlled intrinsic apoptotic pathway . Consistent with our findings, dexmedetomidine has been shown to decrease the expression of pro-apoptotic factors such as caspase-3  and Bax whilst increasing the expression of anti-apoptotic Bcl-2 and Mdm-2  in the brain. Akt signaling has previously been shown to be critical to recovery from renal IRI injury and therefore, it can be concluded that dexmedetomidine protection may involve Akt signaling.
In addition to its cytoprotective effects, our studies demonstrated that dexmedetomidine suppressed the TLR-4 mediated inflammatory circuitry. Expression of TLR-4 has been shown to be triggered through endogenous ligands, including damage-associated molecular patterns (DAMPs) and cytokines. High mobility group box 1 (HMGB-1) is a potent DAMP released from dying cells during tissue ischemia. It binds to TLR-4 initiating down-stream NF-κB signaling cascade  substantially augmenting the synthesis of pro-inflammatory cytokines such as TNF-α and IL-1β . Recent work by Wu et al.,  demonstrated that TLR4-deficient or the adaptor molecule myD88-deficient mice were protected from both kidney dysfunction and histological damage induced by renal IRI. Generation of pro-inflammatory cytokine (IL-6, IL-1β, and TNF-α) and chemokines (MIP-2 and MCP-1) was inhibited, together with a parallel decline of macrophage and neutrophil infiltration. Pre-treatment of dexmedetomine resulted in almost complete attenuation of TLR-4 expression associated with decreased cell death of tubular epithelial cells. We propose that dexmedetomidine may have prevented the increased expression of TLR-4 by attenuating tissue injury (evidenced by lower systemic HMGB1 levels and reduced TUNEL staining) and through co-existent anti-inflammatory actions [39–41] (Figure 8). Herein, we did not further explore the well described anti-inflammatory effects of dexmedetomidine (beyond HMGB1 levels); however, dexmedetomidine reduces systemic levels of IL-6 and TNF-α following lipopolysaccharide infusion in rats  and following cardiac surgery  and sepsis in humans . It is, therefore, plausible that the anti-inflammatory actions of dexmedetomidine contributed to the reduced TLR-4 expression following renal ischemia.
Our study showed a marked improvement in renal morphology and function with reduced nitrogenous waste accumulation following treatment of dexmedetomidine. This protection was attenuated by atipamezole, an α2 adrenoreceptor antagonist, confirming dependence on α2-adrenoceptor agonism. Similarly dexmedetomidine's neuroprotective effect is mediated by α2-adrenoceptor signaling . Consistent with evidence from neuroprotection, our in vitro data suggest that the primary effect of dexmedetomidine is cytoprotection; nonetheless, in vivo it is likely that improved renal blood flow may have contributed to improved renal function and recovery from ischemia. Indeed modulation of vasoreactivity, through reduced sympathetic drive, has been shown to be an important mechanism of α2 adrenoceptor agonist renoprotection [21, 24, 25]. In a model of radiocontrast nephropathy α2-adrenoceptor activation with dexmedetomidine resulted in improved renal function, an effect attributable to improved renal blood flow . However, α2-adrenoceptor activation was not associated with cytoprotection from radiocontrast exposure in vitro  indicating that there are differing mechanisms of radiocontrast and ischemic injury in the kidney. The local responses to α2-adrenoceptor activation in the kidney include vasodilatation , inhibition of renin release, increased glomerular filtration and increased secretion of sodium and water [43, 44]. α2-adrenoceptor agonists may preserve glomerular filtration by preventing reduced renal blood flow following reperfusion associated vasospasm. They may also provoke diuresis by opposing the activity of arginine vasopressin in the collecting duct as well reducing aquaporin expression . In combination, cytoprotection, improved glomerular filtration and diuretic actions may have improved renal function following ischemic injury.
α2-adrenoceptor agonists have diverse utility in the perioperative period; their renoprotective qualities are complemented by their analgesic qualities that reduce the necessity of other analgesics. Reduced use of non-steroidal anti-inflammatory drugs and opioids may be of particular interest as non-steroidal anti-inflammatory drugs increase the risk of AKI and opioids accumulate in AKI. Furthermore, the hemodynamic control, cardioprotection and mild diuretic properties of α2-adrenoceptor agonists may indirectly support renal function. We consider there are multiple reasons to consider a large prospective randomized controlled trial of the reno-protective qualities of α2-adrenoceptor agonists.
AKI associated with ischemia-reperfusion injury is a significant contributor to morbidity and mortality in the perioperative period. dexmedetomidine provides renoprotection against renal IRI whether given as a prophylactic or therapeutic measure. Our data complement preliminary clinical data showing that prophylactic clonidine treatment prevented renal dysfunction attributable to cardiac surgery and that dexmedetomidine improved renal function following thoracic surgery. If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.
Acute kidney injury following surgery significantly increases mortality with no proven preventative therapy.
The α2 adrenoceptor agonist dexmedetomidine has organoprotective properties.
Dexmedetomidine activates cell survival signal pAKT via α2 adrenoceptors to reduce cell death and HMGB1 release and subsequently inhibits TLR4 signaling to provide renoprotection.
Dexmedetomidine may have both cytoprotective and anti-inflammatory effects to protect against renal injury following ischemia-reperfusion.
If our data can be extrapolated to clinical settings, dexmedetomidine may prove protective against IRI associated acute renal failure.
acute kidney injury
a serine/threonine protein kinase
damage-associated molecular patterns
human kidney proximal tubular cells
high-mobility group protein B1
3- (4,5-Dimethyl-2-thiazolyl) -2, 5-diphenyl -2H- tetrazolium bromide
nuclear factor kappa-light-chain-enhancer of activated B cells
oxygen glucose deprivation
toll-like receptor 4
tumor necrosis factor α
terminal deoxynucleotidyl transferase dUTP nick end labeling.
Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet. 2004, 364: 1814-1827. 10.1016/S0140-6736(04)17406-0.
Stafford-Smith M, Shaw A, Swaminathan M: Cardiac surgery and acute kidney injury: emerging concepts. Curr Opin Crit Care. 2009, 15: 498-502. 10.1097/MCC.0b013e328332f753.
Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV: Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol. 1998, 153: 557-566. 10.1016/S0002-9440(10)65598-8.
Kashyap VS, Cambria RP, Davison JK, L'Italien GJ: Renal failure after thoracoabdominal aortic surgery. J Vasc Surg. 1997, 26: 949-955. 10.1016/S0741-5214(97)70006-5.
Kupiec-Weglinski JW, Busuttil RW: Ischemia and reperfusion injury in liver transplantation. Transplant Proc. 2005, 37: 1653-1656. 10.1016/j.transproceed.2005.03.134.
Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth. 2005, 95: 20-32. 10.1093/bja/aei018.
Borthwick E, Ferguson A: Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ. 2010, 341: c3365-10.1136/bmj.c3365.
Englberger L, Suri RM, Greason KL, Burkhart HM, Sundt TM, Daly RC, Schaff HV: Deep hypothermic circulatory arrest is not a risk factor for acute kidney injury in thoracic aortic surgery. J Thorac Cardiovasc Surg. 2011, 141: 552-558. 10.1016/j.jtcvs.2010.02.045.
Cerda J, Lameire N, Eggers P, Pannu N, Uchino S, Wang H, Bagga A, Levin A: Epidemiology of acute kidney injury. Clin J Am Soc Nephrol. 2008, 3: 881-886. 10.2215/CJN.04961107.
Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004, 114: 5-14.
Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000, 190: 255-266. 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6.
Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J: The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010, 6: 224-235. 10.1038/nrneph.2010.16.
Arslan F, Keogh B, McGuirk P, Parker AE: TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. 2010, 2010: 704202-
Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005, 5: 331-342. 10.1038/nri1594.
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006, 26: 174-179. 10.1097/01.shk.0000225404.51320.82.
Hoste EA, Kellum JA: Incidence, classification, and outcomes of acute kidney injury. Contrib Nephrol. 2007, 156: 32-38.
Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ: Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000, 90: 699-705. 10.1097/00000539-200003000-00035.
Sanders RD, Maze M: Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007, 8: 25-33.
Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M: Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004, 502: 87-97. 10.1016/j.ejphar.2004.08.044.
Kuhmonen J, Pokorny J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen P, Sivenius J: Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997, 87: 371-377. 10.1097/00000542-199708000-00025.
Billings FTt, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT: alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008, 295: F741-748. 10.1152/ajprenal.90244.2008.
Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR, Sladen RN: Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth. 2006, 18: 422-426. 10.1016/j.jclinane.2006.02.005.
Kulka PJ, Tryba M, Zenz M: Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med. 1996, 24: 947-952. 10.1097/00003246-199606000-00012.
Solez K, Ideura T, Silvia CB, Hamilton B, Saito H: Clonidine after renal ischemia to lessen acute renal failure and microvascular damage. Kidney Int. 1980, 18: 309-322. 10.1038/ki.1980.141.
Tsutsui H, Sugiura T, Hayashi K, Ohkita M, Takaoka M, Yukimura T, Matsumura Y: Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009, 603: 73-78. 10.1016/j.ejphar.2008.12.012.
Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood). 235: 886-891.
Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M: Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology. 2009, 110: 1077-1085. 10.1097/ALN.0b013e31819daedd.
Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M: Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol. 2009, 20: 713-720. 10.1681/ASN.2008070712.
Satake A, Takaoka M, Nishikawa M, Yuba M, Shibata Y, Okumura K, Kitano K, Tsutsui H, Fujii K, Kobuchi S, Ohkita M, Matsumura Y: Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney Int. 2008, 73: 308-317. 10.1038/sj.ki.5002690.
Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous danger signaling. Mol Med. 2008, 14: 476-484.
Franks NP, Lieb WR: Volatile general anaesthetics activate a novel neuronal K+ current. Nature. 1988, 333: 662-664. 10.1038/333662a0.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4: 988-1004. 10.1038/nrd1902.
Dahmani S, Rouelle D, Gressens P, Mantz J: Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology. 2005, 103: 969-977. 10.1097/00000542-200511000-00011.
Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E: The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003, 96: 524-531.
O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007, 7: 353-364. 10.1038/nri2079.
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001, 2: 675-680. 10.1038/90609.
Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007, 117: 2847-2859. 10.1172/JCI31008.
Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K: Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004, 32: 1322-1326. 10.1097/01.CCM.0000128579.84228.2A.
Venn RM, Bryant A, Hall GM, Grounds RM: Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth. 2001, 86: 650-656. 10.1093/bja/86.5.650.
Sanders RD, Hussell T, Maze M: Sedation & immunomodulation. Crit Care Clin. 2009, 25: 551-570. 10.1016/j.ccc.2009.05.001.
Memis D, Hekimoglu S, Vatan I, Yandim T, Yuksel M, Sut N: Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth. 2007, 98: 550-552. 10.1093/bja/aem017.
Gertler R, Brown HC, Mitchell DH, Silvius EN: Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001, 14: 13-21.
Philipp M, Brede M, Hein L: Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002, 283: R287-295.
Junaid A, Cui L, Penner SB, Smyth DD: Regulation of aquaporin-2 expression by the alpha(2)-adrenoceptor agonist clonidine in the rat. J Pharmacol Exp Ther. 1999, 291: 920-923.
This work was supported by a grant (RGP09) from the European Society of Anesthesiology, Brussels, Belgium, to DM and a grant (2010ZX09401-306-1-3) from the State Science and Technology Commission, China to PX. JG was supported by a scholarship from the Chinese Scholarship Committee, Beijing, China.
MM has been a consultant for Abbott Laboratories, Abbott Park, IL, USA, to facilitate registration of dexmedetomidine in the United States. There is no conflict of interest involving the other authors.
JG carried out the in vivo and in vitro studies and drafted the manuscript. PS carried out the in vivo studies and drafted the manuscript. HZ, HRW and RDS drafted the manuscript. NT carried out ELISA measurements. PX and MM participated in the design of the study. DM designed studies, analysed data and drafted the manuscript. All authors read and approved the final manuscript.
Jianteng Gu, Pamela Sun contributed equally to this work.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Gu, J., Sun, P., Zhao, H. et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care 15, R153 (2011). https://doi.org/10.1186/cc10283
- TLR4 Expression
- HMGB1 Level
- Renal Pedicle